Advanced Wound Care and Regenerative Medicine Access and Reform Act
Impact
One of the key changes proposed by HB6852 is the establishment of a new reimbursement model that will ensure equivalent payment for skin substitute products regardless of the outpatient setting where these products are applied. This aims to standardize costs and improve patient access to high-quality wound care treatments, which have often faced obstacles due to inconsistent reimbursements. By creating a specific billing and payment code for skin substitute products, the bill intends to enhance clarity and efficiency in the billing process.
Summary
House Bill 6852, titled the 'Advanced Wound Care and Regenerative Medicine Access and Reform Act', seeks to amend the Social Security Act to reform payment structures for skin substitute products under the Medicare program. This legislation aims to improve accessibility and reimbursement for innovative wound care treatments by integrating skin substitute products into Medicare's reimbursable item list, which is expected to take effect on January 1, 2026. By including these products, the bill recognizes the increasing importance of advanced wound care in medical practices.
Contention
Despite its potential benefits, there may be contention surrounding the implementation of the new payment rules, particularly regarding the identification of outlier providers and the introduction of pre-authorization requirements for claims exceeding certain thresholds. Concerns may arise about the efficacy of these procedures in terms of patient care and provider reimbursement timelines, as stringent controls might create barriers for timely access to essential wound care treatments. Furthermore, opponents may argue that these regulations could inadvertently stifle innovation in wound care solutions if not carefully managed.